The safety and efficacy of apixaban: where do we stand in 2013?

Author： de Souza Brito Flavio   Lopes Renato D   Alexander John H  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.4, 2013-07, pp. : 559-567

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

JC virus in colorectal cancer: where do we stand?

By Matalka Ismail   Swedan Samer   Khabaz Mohamad Nidal   Barahmeh Myassar  

Future Virology, Vol. 8, Iss. 6, 2013-06 ,pp. : 607-615

Future Medicine

Access to resources Recommend Favorite

X-ray structural information of GPCRs in drug design: what are the limitations and where do we go?

By Topiol Sid  

Expert Opinion on Drug Discovery, Vol. 8, Iss. 6, 2013-10 ,pp. : 607-620

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?

By Giembycz M.A.  

Drugs, Vol. 59, Iss. 2, 2000-02 ,pp. : 193-212

Adis International

Access to resources Recommend Favorite

Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?

By Lazaro A.  

PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. : 943-961

Adis International

Access to resources Recommend Favorite

Therapy for Osteosarcoma: Where Do We Go From Here?

By Chou Alexander J.  

Pediatric Drugs, Vol. 10, Iss. 5, 2008-01 ,pp. : 315-327

Adis International

Access to resources Recommend Favorite